$EDIT
Editas Medicine, Inc. Stock $edit

$edit Overview Financials Valuation SEC Filings Company Website

2025 Q1 Form 10-K Financial Statement

#000165066425000022 Filed on March 05, 2025

Income Statement

Concept	2025 Q1	2024 Q4	2024
Revenue			$32.31M
YoY Change			-58.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development			$199.2M
YoY Change			12.16%
% of Gross Profit
Depreciation & Amortization			$5.800M
YoY Change			-4.92%
% of Gross Profit
Operating Expenses			$283.5M
YoY Change			14.62%
Operating Profit			-$251.2M
YoY Change			48.45%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net			$14.06M
YoY Change			-11.92%
Pretax Income
YoY Change
Income Tax			$0.00
% Of Pretax Income
Net Earnings			-$237.1M
YoY Change			54.74%
Net Earnings / Revenue			-733.72%
Basic Earnings Per Share			-$2.88
Diluted Earnings Per Share			-$2.88
COMMON SHARES
Basic Shares Outstanding	82.98M shares	82.55M shares	82.34M shares
Diluted Shares Outstanding			82.34M shares

Balance Sheet

Concept	2025 Q1	2024 Q4	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$131.5M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$289.3M
YoY Change		-15.11%
LONG-TERM ASSETS
Property, Plant & Equipment		$14.50M
YoY Change		20.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$5.223M
YoY Change		-39.18%
Total Long-Term Assets		$52.27M
YoY Change		-66.98%
TOTAL ASSETS
Total Short-Term Assets		$289.3M
Total Long-Term Assets		$52.27M
Total Assets		$341.6M
YoY Change		-31.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$5.493M
YoY Change		-33.57%
Accrued Expenses		$45.86M
YoY Change		32.68%
Deferred Revenue		$6.221M
YoY Change		-24.33%
Short-Term Debt
YoY Change
Long-Term Debt Due		$5.000M
YoY Change
Total Short-Term Liabilities		$77.23M
YoY Change		22.16%
LONG-TERM LIABILITIES
Long-Term Debt		$52.43M
YoY Change
Other Long-Term Liabilities		$3.072M
YoY Change		70.67%
Total Long-Term Liabilities		$55.51M
YoY Change		2983.67%
TOTAL LIABILITIES
Total Short-Term Liabilities		$77.23M
Total Long-Term Liabilities		$55.51M
Total Liabilities		$207.3M
YoY Change		38.16%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.500B
YoY Change		25.0%
Common Stock		$1.602B
YoY Change		1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$134.3M
YoY Change
Total Liabilities & Shareholders Equity		$341.6M
YoY Change		-31.57%

Cashflow Statement

Concept	2025 Q1	2024 Q4	2024
OPERATING ACTIVITIES
Net Income			-$237.1M
YoY Change			54.74%
Depreciation, Depletion And Amortization			$5.800M
YoY Change			-4.92%
Cash From Operating Activities			-$210.3M
YoY Change			59.09%
INVESTING ACTIVITIES
Capital Expenditures			$8.826M
YoY Change			87.03%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			$162.1M
YoY Change			-4445.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$56.03M
YoY Change			-52.54%
NET CHANGE
Cash From Operating Activities			-$210.3M
Cash From Investing Activities			$162.1M
Cash From Financing Activities			$56.03M
Net Change In Cash			$7.889M
YoY Change			-144.15%
FREE CASH FLOW
Cash From Operating Activities			-$210.3M
Capital Expenditures			$8.826M
Free Cash Flow			-$219.1M
YoY Change			60.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	349097000	usd
CY2024	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	193000	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	919000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	979000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56027000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118039000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7889000	usd
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001650664
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4097528
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Hurley Street
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02141
CY2024	dei	City Area Code CityAreaCode	617
CY2024	dei	Local Phone Number LocalPhoneNumber	401-9000
CY2024	dei	Security12b Title Security12bTitle	Common Stock
CY2024	dei	Trading Symbol TradingSymbol	EDIT
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Public Float EntityPublicFloat	383847152	usd
CY2025Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82976284	shares
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21417000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-153219000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-220432000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	21417000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	19798000	usd
CY2024	us-gaap	Depreciation Depreciation	5809000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-153219000	usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	193000	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135418000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127529000	usd
CY2022	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2024	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2023	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2024#ServiceMember
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashAndCashEquivalentsNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-12-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024	dei	Entity Registrant Name EntityRegistrantName	EDITAS MEDICINE, INC.
CY2024	cyd	Cybersecurity Risk Management Processes Integrated Flag CybersecurityRiskManagementProcessesIntegratedFlag	true
CY2024	cyd	Cybersecurity Risk Third Party Oversight And Identification Processes Flag CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag	true
CY2024	cyd	Cybersecurity Risk Management Third Party Engaged Flag CybersecurityRiskManagementThirdPartyEngagedFlag	true
CY2024	cyd	Cybersecurity Risk Materially Affected Or Reasonably Likely To Materially Affect Registrant Flag CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag	false
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Report To Board Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag	true
CY2024	cyd	Cybersecurity Risk Management Positions Or Committees Responsible Flag CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag	true
CY2024	dei	Auditor Firm AuditorFirmId	42
CY2024	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2024	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131541000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123652000	usd
CY2024Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	138372000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	199459000	usd
CY2024Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	16266000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	10187000	usd
CY2024Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3136000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7531000	usd
CY2024Q4	us-gaap	Assets Current AssetsCurrent	289315000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	340829000	usd
CY2024Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	104024000	usd
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14497000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12032000	usd
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32554000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33680000	usd
CY2024Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5223000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8588000	usd
CY2024Q4	us-gaap	Assets Assets	341589000	usd
CY2023Q4	us-gaap	Assets Assets	499153000	usd
CY2024Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5493000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8269000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45859000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34563000	usd
CY2024Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5000000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2024Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6221000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8221000	usd
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14652000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12164000	usd
CY2024Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77225000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	63217000	usd
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20380000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24372000	usd
CY2024Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52434000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2024Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	54204000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	60667000	usd
CY2024Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3072000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1800000	usd
CY2024Q4	us-gaap	Liabilities Liabilities	207315000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	150056000	usd
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	195000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	195000000	shares
CY2024Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82734696	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81767263	shares
CY2024Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82734696	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81767263	shares
CY2024Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2024Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1602441000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1580241000	usd
CY2024Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	268000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	198000	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1468443000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1231350000	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	134274000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	349097000	usd
CY2024Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	341589000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	499153000	usd
CY2024	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32314000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	78123000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19712000	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	199247000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	177651000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	174958000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71987000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	69653000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	70704000	usd
CY2024	us-gaap	Restructuring Charges RestructuringCharges	12232000	usd
CY2023	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2022	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	283466000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	247304000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	245662000	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-251152000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-169181000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-225950000	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1604000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2024	us-gaap	Investment Income Net InvestmentIncomeNet	14062000	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	17566000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	5518000	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14059000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15962000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5518000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-237093000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-220432000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.88
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.88
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.02
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.21
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.21
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82338220	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82338220	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	75965633	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	75965633	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68664822	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68664822	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-237093000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-153219000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-220432000	usd
CY2024	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	70000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3799000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3108000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-237023000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-149420000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-223540000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	553642000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	305000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29294000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	979000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3108000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-220432000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	360680000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	117079000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19798000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	919000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3799000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-153219000	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	590000	usd
CY2024	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	70000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-237093000	usd
CY2024Q4	us-gaap	Stockholders Equity StockholdersEquity	134274000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-237093000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	29294000	usd
CY2023	us-gaap	Depreciation Depreciation	6064000	usd
CY2022	us-gaap	Depreciation Depreciation	6337000	usd
CY2024	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	5791000	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	4823000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	724000	usd
CY2024	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-149000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2024	edit	Non Cash Interest Expense On Liability For Sale Of Future Revenues NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues	2190000	usd
CY2023	edit	Non Cash Interest Expense On Liability For Sale Of Future Revenues NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues	0	usd
CY2022	edit	Non Cash Interest Expense On Liability For Sale Of Future Revenues NonCashInterestExpenseOnLiabilityForSaleOfFutureRevenues	0	usd
CY2024	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	415000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1596000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6079000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5042000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4878000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4396000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	197000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	137000	usd
CY2024	edit	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-1126000	usd
CY2023	edit	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-9968000	usd
CY2022	edit	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	17475000	usd
CY2024	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3366000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	3335000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1558000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2286000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1492000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4368000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11623000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4114000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10505000	usd
CY2024	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8463000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3333000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1504000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7410000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	17568000	usd
CY2024	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1271000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1800000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-210284000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-132178000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-177349000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8826000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4719000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4118000	usd
CY2024	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0	usd
CY2023	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	18000	usd
CY2024	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	86217000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	258517000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	315186000	usd
CY2024	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	257189000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	259505000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	433354000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	162146000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3731000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	114068000	usd
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117079000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024	edit	Proceeds From Issuance Of Debt Net Of Payment Of Debt Issuance Costs ProceedsFromIssuanceOfDebtNetOfPaymentOfDebtIssuanceCosts	55244000	usd
CY2023	edit	Proceeds From Issuance Of Debt Net Of Payment Of Debt Issuance Costs ProceedsFromIssuanceOfDebtNetOfPaymentOfDebtIssuanceCosts		usd
CY2022	edit	Proceeds From Issuance Of Debt Net Of Payment Of Debt Issuance Costs ProceedsFromIssuanceOfDebtNetOfPaymentOfDebtIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	41000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	305000	usd
CY2024	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	590000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1284000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17870000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-61997000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127529000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145399000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207396000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145399000	usd
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131541000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123652000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	141522000	usd
CY2024Q4	us-gaap	Restricted Cash RestrictedCash	3877000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	3877000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3877000	usd
CY2024Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135418000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127529000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	145399000	usd
CY2024Q4	us-gaap	Restricted Cash RestrictedCash	3877000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	3877000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	3877000	usd
CY2024	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	65000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	845000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1440000	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	18447000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	12428000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	14851000	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	794000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2752000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	24545000	usd
CY2024	edit	Commencement Of Right Of Use Asset CommencementOfRightOfUseAsset	7844000	usd
CY2023	edit	Commencement Of Right Of Use Asset CommencementOfRightOfUseAsset	0	usd
CY2022	edit	Commencement Of Right Of Use Asset CommencementOfRightOfUseAsset	5316000	usd
CY2024	edit	Modification Of Right Of Use Asset ModificationOfRightOfUseAsset	2683000	usd
CY2023	edit	Modification Of Right Of Use Asset ModificationOfRightOfUseAsset	0	usd
CY2022	edit	Modification Of Right Of Use Asset ModificationOfRightOfUseAsset	0	usd
CY2024	us-gaap	Stock Issued1 StockIssued1	1479000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Editas Medicine, Inc. (the “Company”) is an early stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc. (“Juno Therapeutics”), a wholly owned subsidiary of the Bristol-Myers Squibb Company (“BMS”), payments received under its former strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliates, “Allergan”), which was terminated in August 2020, payments received under our purchase and sale agreement with DRI Healthcare Acquisitions LP, and payments received in conjunction with the Company’s license agreement with Vertex Pharmaceuticals, Inc (“Vertex”, and such agreement, the “Vertex License Agreement”). </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company has raised an aggregate of $1.0 billion in net proceeds through the sale of shares of its common stock in public offerings and at-the-market offerings. The Company also has funded its business from payments received under our purchase and sale agreement with DRI Healthcare Acquisitions LP, payments received under its license agreement with Vertex, its research collaboration with BMS through its wholly owned subsidiary June Therapeutics and its former strategic alliance with Allergan (which was terminated in August 2020). As of December 31, 2024, the Company had cash, cash equivalents and marketable securities of $269.9 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a common stock sales agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (“TD Cowen”), under which the Company from time to time can issue and sell shares of its common stock through TD Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $300.0 million (the “Prior ATM Facility”). The Company amended the common stock sales agreement with TD Cowen in February 2024 in connection with filing a new registration statement. As of December 31, 2024 the Company has not sold any shares of its common stock under the Prior ATM Facility. In March 2025, the Company further amended the common stock sales agreement with TD Cowen in connection with amending its shelf registration statement following the loss of its status as a “well-known seasoned issuer” (as defined under Rule 405 of the Securities Act of 1933, as amended), lowering the amount of shares of common stock it may issue and sell through TD Cowen to aggregate gross sale proceeds of up to $150.0 million (the “ATM Facility”). As of December 31, 2024, the Company had not sold any shares of its common stock under the ATM Facility. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred annual net operating losses in every year since its inception. The Company has an accumulated deficit of $1.5 billion at December 31, 2024. As of March 5, 2025, the issuance date of the consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of the consolidate financial statements. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</span></div>
CY2024	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1000000000.0	usd
CY2024Q4	edit	Cash Cash Equivalents And Marketable Securities Investments Total CashCashEquivalentsAndMarketableSecuritiesInvestmentsTotal	269900000	usd
CY2024Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1500000000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, stock-based compensation expense, the accrual for research and development expenses, valuations of in-process research and development assets, effective interest rates and deferred tax valuation allowances. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span></div>
CY2024Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3900000	usd
CY2024Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	131541000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123652000	usd
CY2024Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3877000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3877000	usd
CY2024Q4	edit	Cash Cash Equivalents Restricted Cash Restricted Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsRestrictedCashRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale	135418000	usd
CY2023Q4	edit	Cash Cash Equivalents Restricted Cash Restricted Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsRestrictedCashRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale	127529000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2024	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2024Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to a concentration of credit risk are cash, cash equivalents, marketable securities and receivables owed to the Company from collaboration partners. The Company’s cash, cash equivalents and marketable securities are held in accounts at a financial </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institution that may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.</span></div>
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	269645000	usd
CY2024Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	289000	usd
CY2024Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	21000	usd
CY2024Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	269913000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	426937000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	611000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	413000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	427135000	usd
CY2024Q4	edit	Marketable Securities Noncurrent Number Of Securities MarketableSecuritiesNoncurrentNumberOfSecurities	0	security
CY2024	edit	Marketable Securities Remaining Maturity Term MarketableSecuritiesRemainingMaturityTerm	P1Y
CY2024Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46145000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	38292000	usd
CY2024Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	31648000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26260000	usd
CY2024Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14497000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12032000	usd
CY2024	us-gaap	Depreciation Depreciation	5800000	usd
CY2023	us-gaap	Depreciation Depreciation	6100000	usd
CY2022	us-gaap	Depreciation Depreciation	6300000	usd
CY2024Q4	edit	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	11630000	usd
CY2023Q4	edit	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	16204000	usd
CY2024Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11516000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11280000	usd
CY2024Q4	edit	Sublicense And License Fees Current SublicenseAndLicenseFeesCurrent	6609000	usd
CY2023Q4	edit	Sublicense And License Fees Current SublicenseAndLicenseFeesCurrent	5063000	usd
CY2024Q4	edit	Intellectual Property And Patent Related Fees Current IntellectualPropertyAndPatentRelatedFeesCurrent	1471000	usd
CY2023Q4	edit	Intellectual Property And Patent Related Fees Current IntellectualPropertyAndPatentRelatedFeesCurrent	983000	usd
CY2024Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1593000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	750000	usd
CY2024Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	808000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	283000	usd
CY2024Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45859000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	34563000	usd
CY2024Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32554000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33680000	usd
CY2024Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	14652000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12164000	usd
CY2024Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20380000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24372000	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	21000000.0	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	15200000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	13600000	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	2800000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	3300000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	3000000.0	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	17143000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	9728000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7076000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6000000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	39947000	usd
CY2024Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4915000	usd
CY2024Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	35032000	usd
CY2024Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2024Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.091
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	10187000	usd
CY2024	edit	Accounts Receivable Additions AccountsReceivableAdditions	22644000	usd
CY2024	edit	Accounts Receivable Deductions AccountsReceivableDeductions	16565000	usd
CY2024Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	16266000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	68888000	usd
CY2024	edit	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	0	usd
CY2024	edit	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	8463000	usd
CY2024Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	60425000	usd
CY2024	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	8463000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
CY2024	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
CY2023	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q4	edit	Number Of Inducement Grants NumberOfInducementGrants	3	grant
CY2024Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	22692016	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20542532	shares
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21417000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19798000	usd
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	2
CY2024	edit	Defined Contribution Plan Maximum Annual Contributions Per Employee Matching Contribution Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeMatchingContributionAmount	7000	usd
CY2024	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2024	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1700000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1400000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.060
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.026
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.025
CY2024	edit	Effective Income Tax Rate Reconciliation Covered Employees Percent EffectiveIncomeTaxRateReconciliationCoveredEmployeesPercent	0.002
CY2023	edit	Effective Income Tax Rate Reconciliation Covered Employees Percent EffectiveIncomeTaxRateReconciliationCoveredEmployeesPercent	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.043
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.002
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.026
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.045
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.255
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.218
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.013
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	170770000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	153365000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	31766000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	25646000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	6763000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3975000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	52178000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	56955000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	84703000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	60891000	usd
CY2024Q4	edit	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	9134000	usd
CY2023Q4	edit	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	9966000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	15755000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	18791000	usd
CY2024Q4	edit	Deferred Tax Assets Liabilities Depreciation And Amortization Net DeferredTaxAssetsLiabilitiesDepreciationAndAmortizationNet	978000	usd
CY2023Q4	edit	Deferred Tax Assets Liabilities Depreciation And Amortization Net DeferredTaxAssetsLiabilitiesDepreciationAndAmortizationNet	905000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10431000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7323000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14976000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2024Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	397454000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	337817000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	388967000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	328630000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8487000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9187000	usd
CY2024Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8487000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9187000	usd
CY2024Q4	edit	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	0	usd
CY2023Q4	edit	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	0	usd
CY2024Q4	edit	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	8487000	usd
CY2023Q4	edit	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	9187000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024	edit	Increase Decrease In Deferred Tax Assets Research And Devolopment IncreaseDecreaseInDeferredTaxAssetsResearchAndDevolopment	84700000	usd
CY2024Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	389000000.0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	328600000	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	60300000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13659000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2020000	usd
CY2024	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2024Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15679000	usd
CY2024Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15700000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13700000	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9982533	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8256792	shares
CY2024	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	57000000	usd
CY2024	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1756000	usd
CY2024	us-gaap	Interest Expense Debt InterestExpenseDebt	2128000	usd
CY2024	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	62000	usd
CY2024Q4	us-gaap	Long Term Debt LongTermDebt	57434000	usd
CY2024	us-gaap	Restructuring Charges RestructuringCharges	12232000	usd
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024	edit	Number Of Customers NumberOfCustomers	2	numberofcustomer
CY2023	edit	Number Of Customers NumberOfCustomers	1	numberofcustomer
CY2024Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	ecd	Insider Trd Policies Proc Adopted Flag InsiderTrdPoliciesProcAdoptedFlag	true

Files In Submission

Name	View Source	Status
0001650664-25-000022-index-headers.html	Edgar Link	pending
0001650664-25-000022-index.html	Edgar Link	pending
0001650664-25-000022.txt	Edgar Link	pending
0001650664-25-000022-xbrl.zip	Edgar Link	pending
edit-20221231xexx3111.htm	Edgar Link	pending
edit-20221231xexx3121.htm	Edgar Link	pending
edit-20221231xexx3211.htm	Edgar Link	pending
edit-20241231.htm	Edgar Link	pending
edit-20241231.xsd	Edgar Link	pending
edit-20241231_g1.jpg	Edgar Link	pending
edit-20241231_g2.jpg	Edgar Link	pending
ex1015separationagreemen.htm	Edgar Link	pending
ex1015separationagreemen001.jpg	Edgar Link	pending
ex1015separationagreemen002.jpg	Edgar Link	pending
ex1015separationagreemen003.jpg	Edgar Link	pending
ex1015separationagreemen004.jpg	Edgar Link	pending
ex1015separationagreemen005.jpg	Edgar Link	pending
ex1015separationagreemen006.jpg	Edgar Link	pending
ex1015separationagreemen007.jpg	Edgar Link	pending
ex1015separationagreemen008.jpg	Edgar Link	pending
ex1015separationagreemen009.jpg	Edgar Link	pending
ex1015separationagreemen010.jpg	Edgar Link	pending
ex1015separationagreemen011.jpg	Edgar Link	pending
ex1015separationagreemen012.jpg	Edgar Link	pending
ex1015separationagreemen013.jpg	Edgar Link	pending
ex1015separationagreemen014.jpg	Edgar Link	pending
ex1015separationagreemen015.jpg	Edgar Link	pending
ex1025-purchaseandsaleag.htm	Edgar Link	pending
ex1025-purchaseandsaleag001.jpg	Edgar Link	pending
ex1025-purchaseandsaleag002.jpg	Edgar Link	pending
ex1025-purchaseandsaleag003.jpg	Edgar Link	pending
ex1025-purchaseandsaleag004.jpg	Edgar Link	pending
ex1025-purchaseandsaleag005.jpg	Edgar Link	pending
ex1025-purchaseandsaleag006.jpg	Edgar Link	pending
ex1025-purchaseandsaleag007.jpg	Edgar Link	pending
ex1025-purchaseandsaleag008.jpg	Edgar Link	pending
ex1025-purchaseandsaleag009.jpg	Edgar Link	pending
ex1025-purchaseandsaleag010.jpg	Edgar Link	pending
ex1025-purchaseandsaleag011.jpg	Edgar Link	pending
ex1025-purchaseandsaleag012.jpg	Edgar Link	pending
ex1025-purchaseandsaleag013.jpg	Edgar Link	pending
ex1025-purchaseandsaleag014.jpg	Edgar Link	pending
ex1025-purchaseandsaleag015.jpg	Edgar Link	pending
ex1025-purchaseandsaleag016.jpg	Edgar Link	pending
ex1025-purchaseandsaleag017.jpg	Edgar Link	pending
ex1025-purchaseandsaleag018.jpg	Edgar Link	pending
ex1025-purchaseandsaleag019.jpg	Edgar Link	pending
ex1025-purchaseandsaleag020.jpg	Edgar Link	pending
ex1025-purchaseandsaleag021.jpg	Edgar Link	pending
ex1025-purchaseandsaleag022.jpg	Edgar Link	pending
edit-20241231_lab.xml	Edgar Link	unprocessable
edit-20241231_pre.xml	Edgar Link	unprocessable
edit-20241231_htm.xml	Edgar Link	completed
ex1025-purchaseandsaleag023.jpg	Edgar Link	pending
ex1025-purchaseandsaleag024.jpg	Edgar Link	pending
ex1025-purchaseandsaleag025.jpg	Edgar Link	pending
ex1025-purchaseandsaleag026.jpg	Edgar Link	pending
ex1025-purchaseandsaleag027.jpg	Edgar Link	pending
ex1025-purchaseandsaleag028.jpg	Edgar Link	pending
ex1025-purchaseandsaleag029.jpg	Edgar Link	pending
ex1025-purchaseandsaleag030.jpg	Edgar Link	pending
ex1025-purchaseandsaleag031.jpg	Edgar Link	pending
ex1025-purchaseandsaleag032.jpg	Edgar Link	pending
ex1025-purchaseandsaleag033.jpg	Edgar Link	pending
ex1025-purchaseandsaleag034.jpg	Edgar Link	pending
ex1025-purchaseandsaleag035.jpg	Edgar Link	pending
ex1025-purchaseandsaleag036.jpg	Edgar Link	pending
ex1025-purchaseandsaleag037.jpg	Edgar Link	pending
ex1025-purchaseandsaleag038.jpg	Edgar Link	pending
ex1025-purchaseandsaleag039.jpg	Edgar Link	pending
ex1025-purchaseandsaleag040.jpg	Edgar Link	pending
ex1025-purchaseandsaleag041.jpg	Edgar Link	pending
ex1025-purchaseandsaleag042.jpg	Edgar Link	pending
ex1025-purchaseandsaleag043.jpg	Edgar Link	pending
ex1025-purchaseandsaleag044.jpg	Edgar Link	pending
ex1025-purchaseandsaleag045.jpg	Edgar Link	pending
ex1025-purchaseandsaleag046.jpg	Edgar Link	pending
ex1025-purchaseandsaleag047.jpg	Edgar Link	pending
ex1025-purchaseandsaleag048.jpg	Edgar Link	pending
ex1025-purchaseandsaleag049.jpg	Edgar Link	pending
ex1025-purchaseandsaleag050.jpg	Edgar Link	pending
ex1025-purchaseandsaleag051.jpg	Edgar Link	pending
ex1025-purchaseandsaleag052.jpg	Edgar Link	pending
ex19-editasxinsidertrading.htm	Edgar Link	pending
ex231eyconsent.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
edit-20241231_cal.xml	Edgar Link	unprocessable
edit-20241231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EDIT
Editas Medicine, Inc. Stock $edit

2025 Q1 Form 10-K Financial Statement

#000165066425000022 Filed on March 05, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EDIT Editas Medicine, Inc. Stock $edit

2025 Q1 Form 10-K Financial Statement

#000165066425000022 Filed on March 05, 2025

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EDIT
Editas Medicine, Inc. Stock $edit